178 related articles for article (PubMed ID: 31104743)
1. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
2. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
3. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
4. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
6. Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice.
Bilcke J; Beutels P
Med Decis Making; 2022 May; 42(4):421-435. PubMed ID: 34651515
[TBL] [Abstract][Full Text] [Related]
7. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
8. Output correlations in probabilistic models with multiple alternatives.
Naveršnik K
Eur J Health Econ; 2015 Mar; 16(2):133-9. PubMed ID: 24390145
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment in the cost-disutility plane.
Eckermann S; Briggs A; Willan AR
Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
[TBL] [Abstract][Full Text] [Related]
11. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
12. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
O'Brien BJ; Briggs AH
Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
[TBL] [Abstract][Full Text] [Related]
13. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information.
Campbell JD; McQueen RB; Libby AM; Spackman DE; Carlson JJ; Briggs A
Med Decis Making; 2015 Jul; 35(5):596-607. PubMed ID: 25349188
[TBL] [Abstract][Full Text] [Related]
15. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
16. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
18. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
19. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
Claxton K; Ginnelly L; Sculpher M; Philips Z; Palmer S
Health Technol Assess; 2004 Jul; 8(31):1-103, iii. PubMed ID: 15248937
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
